Markus Galler

Mr. Markus Galler

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MGMarkus Galler
Markus Galler
JRJulian Manuel Michael Rogasch
Julian Manuel Michael Rogasch
KHKai Huang
Kai Huang
HJHenning Jann
Henning Jann
KPKristina Plehm
Kristina Plehm
HAHolger Amthauer
Holger Amthauer
(1) Background: retreatment with radionuclide-labeled somatostatin analogues following disease progression after initial treatment cycles is often referred to as salvage peptide receptor radionuclide therapy (salvage PRRT). Salvage PRRT is shown to have a favorable safety profile in patients with metastatic neuroendocrine tumors (NETs), but numerous questions about the efficacy and prognostic or predictive factors remain to be answered. The purpose of this study was to evaluate two parameters that have shown prognostic significance in progression-free survival (PFS) in initial PRRT treatment, namely the size of the largest lesion (LLS) and the De Ritis ratio (aspartate aminotransferase (AST)/alanine aminotransferase (ALT)), as prognostic factors in the context of salvage PRRT. In addition, the PFS after initial PRRT was evaluated as a predictor of the PFS following salvage PRRT. (2) Methods: retrospective, monocentric analysis in 32 patients with NETs (gastroenteropancreatic, 23; unknown primary, 7; kidney, 1; lung, 1) and progression after initial PRRT undergoing retreatment with [177Lu]Lu-DOTATOC. The prognostic values of LLS, the De Ritis ratio, and PFS after initial treatment cycles regarding PFS following salvage PRRT were evaluated with univariable and multivariable Cox regression. PFS was defined as the time from treatment start until tumor progression according to RECIST 1.1 criteria, death from any cause or start of a new treatment due to progression of cancer-related symptoms (namely carcinoid syndrome). (3) Results: progression after salvage PRRT was observed in 29 of 32 patients with median PFS of 10.8 months (95% confidence interval (CI), 8.0–15.9 months). A higher LLS (hazard ratio (HR): 1.03; p = 0.002) and a higher De Ritis ratio (HR: 2.64; p = 0.047) were associated with shorter PFS after salvage PRRT in univariable Cox regression. PFS after initial PRRT was not associated with PFS following salvage PRRT. In multivariable Cox regression, only LLS remained a significant predictor. (4) Conclusions: the size of the largest lesion is easy to obtain and might help identify patients at risk of early disease progression after salvage PRRT. Validation is required.

6 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
CWChristoph Wetz
Christoph Wetz
TRTristan Ruhwedel
Tristan Ruhwedel
ISImke Schatka
Imke Schatka
JGJane Grabowski
Jane Grabowski
HJHenning Jann
Henning Jann
JRJulian Manuel Michael Rogasch
Julian Manuel Michael Rogasch
Background: Pretherapeutic chromogranin A, alkaline phosphatase (ALP), or De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) are prognostic factors in patients with metastatic neuroendocrine tumors (NET) undergoing peptide receptor radionuclide therapy (PRRT). However, their value for intratherapeutic monitoring remains unclear. We evaluated if changes in plasma markers during PRRT can help identify patients with unfavorable outcomes. Methods: A monocentric retrospective analysis of 141 patients with NET undergoing PRRT with [177Lu]Lu-DOTATOC was conducted. Changes in laboratory parameters were calculated by dividing the values determined immediately before each cycle of PRRT by the pretherapeutic value. Patients with low vs. high PFS were compared with the Wilcoxon rank-sum test. Results: Progression, relapse, or death after PRRT was observed in 103/141 patients. Patients with low PFS showed a significant relative ALP increase before the third (p = 0.014) and fourth (p = 0.039) cycles of PRRT. Kaplan–Meier analysis revealed a median PFS of 24.3 months (95% CI, 20.7–27.8 months) in patients with decreasing ALP values (Δ > 10%) during treatment, 12.5 months (95% CI, 9.2–15.8 months) in patients with increasing ALP values (Δ > 10%), and 17.7 months (95% CI, 13.6–21.8 months) with stable ALP values (Δ ± 10%). Conclusions: Based on these exploratory data, a rise in plasma ALP might indicate disease progression and should be interpreted cautiously during therapy.

19 July 2023 in Biomedical Physics & Engineering Express
Verified
Journal Article
Open access
MGMarkus Galler
Markus Galler
CCC Chibolela
C Chibolela
JRJ M M Rogasch
J M M Rogasch
KHK Huang
K Huang
JSJ Siefert
J Siefert
HAH Amthauer
H Amthauer
Radioligand therapy is a targeted cancer therapy that delivers radiation to tumor cells based on the expression of specific markers on the cell surface. It has become an important treatment option in metastasized neuroendocrine tumors and advanced prostate cancer. The analysis of absorbed doses in radioligand therapies has gained much attention and remains a challenging task due to individual pharmacokinetics. As an alternative to the often used sum of exponential functions in intra-therapeutic dosimetry, a basic compartmental model for the pharmacokinetics of radioligands is described and analyzed in this paper. In its simplest version, the model behavior is determined by the uptake capacity and the association constant and can be solved analytically. The model is extended with rates for excretion from the source compartment and externalization from the lesion compartment. Numerical calculations offer an insight into the quantitative effects of the model parameters on the absorbed dose in the tumor lesion. This analysis helps understanding the importance of clinically relevant factors, e.g. the effect on absorbed doses of modified radioligands that bind to albumin. Using clinical data, the potential application in intra-therapeutic dosimetry is illustrated and compared to the bi-exponential function which lacks a mechanistical basis. While the compartmental model is found to constitute a feasible alternative in these examples, this has to be confirmed by further clinical studies.

1 October 2024 in Physics in Medicine & Biology
Verified
Journal Article
Open access
MGMarkus Galler
Markus Galler
CCC Chibolela
C Chibolela
FTF Thiele
F Thiele
JRJ M M Rogasch
J M M Rogasch
HAH Amthauer
H Amthauer
Objective. 177Lu-based targeted radionuclide therapy (TRT) has become an important cancer treatment option in recent years, in particular in the treatment of advanced prostate cancer and metastasized neuroendocrine tumors. Although it is known from conventional radiotherapy that the temporal dynamics of the dose-rate can be of relevance for tumor cell survival, the analysis of TRT efficacy usually considers only the absorbed dose. Thus, the aim of this theoretical analysis is to shed light on the possible effects of the pattern of dose-rate in TRT on tumor control probability (TCP). Approach. For this purpose, TCP is studied numerically in a typical four-cycle treatment regime based on the mechanistic lethal-potentially lethal model and the Zaider–Minerbo model for TCP including repopulation of tumor cells. Main results. It is shown that the dose-rate pattern in TRT can have a substantial effect on TCP even though the absorbed dose in the tumor lesion is unchanged. These dose-rate effects are particularly evident when repair of potentially lethal lesions is slow. Significance. The results indicate that in some situations in the analysis of the efficacy of TRT it is necessary to consider the full dose-rate pattern instead of the absorbed dose alone. This can be highly relevant for optimization and further development of TRTs. In particular, it could be of relevancy in studying the efficacy of newly emerging treatment concepts that combine the use of TRT and drugs that inhibit DNA damage repair.

1 September 2021 in Chaos: An Interdisciplinary Journal of Nonlinear Science
Verified
Journal Article
Open access
PDF file
MGMarkus Galler
Markus Galler
KLKathy Lüdge
Kathy Lüdge
RHRory Humphries
Rory Humphries
KMKieran Mulchrone
Kieran Mulchrone
PHPhilipp Hövel
Philipp Hövel
Bovine viral diarrhea (BVD) is a disease in cattle with complex transmission dynamics that causes substantial economic losses and affects animal welfare. The infection can be transient or persistent. The mostly asymptomatic persistently infected hosts are the main source for transmission of the virus. This characteristic makes it difficult to control the spreading of BVD. We develop a deterministic compartmental model for the spreading dynamics of BVD within a herd and derive the basic reproduction number. This epidemiological quantity indicates that identification and removal of persistently infected animals is a successful control strategy if the transmission rate of transiently infected animals is small. Removing persistently infected animals from the herd at birth results in recurrent outbreaks with decreasing peak prevalence. We propose a stochastic version of the compartmental model that includes stochasticity in the transmission parameters. This stochasticity leads to sustained oscillations in cases where the deterministic model predicts oscillations with decreasing amplitude. The results provide useful information for the design of control strategies.

30 March 2023 in Nuklearmedizin-Nuclear Medicine
Verified
Journal Article
Closed access
CWChristoph Wetz
Christoph Wetz
TRTristan Ruhwedel
Tristan Ruhwedel
JRJulian Manuel Michael Rogasch
Julian Manuel Michael Rogasch
JSJ. Siefert
J. Siefert
GMG. Metzger
G. Metzger
ISImke Schatka
Imke Schatka
Ziel/Aim Die [177Lu]Lu-Peptid-Rezeptor-Radionuklid-Therapie (PRRT) bildet in der Behandlung von metastasierten gastroenteropankreatischen neuroendokrinen Tumoren (GEP-NET) eine effektive Therapie. Dennoch wird ein frühzeitiger Krankheitsprogress in ca. 20-30% der mit PRRT behandelten Pat. verzeichnet. Das Ziel dieser Studie war die Analyse des Stellenwertes eines Interim-Stagings (iStaging) bzgl. der klinischen Weiterbehandlung nach 2 Zyklen PRRT. Methodik/Methods Retrospektive, unizentrische Analyse von 119 Pat. mit gut differenzierten GEP-NET (G1, n=13; G2, n=106) und Behandlung mit [177Lu]Lu-DOTATOC (Median, 4 [Spannweite, 2-4] Zyklen). Das iStaging [SSR-PET/CT, n=76; SSR-PET/MR, n=18; KM-CT/-MRT+SSR-Szintigraphie, n=25] erfolgte nach 2 Zyklen PRRT und das PFS wurde anhand der RECIST 1.1 Kriterien erhoben. In einem interdisziplinären Setting ist über das weitere therapeutische Prozedere entschieden worden. Für das PFS erfolgten Kaplan-Meier-Analysen. Ergebnisse/Results 83 der 119 Pat. (70%) durchliefen 4 Zyklen PRRT, hingegen wurde die PRRT bei 36 Pat. (30%) nach 2 Zyklen abgebrochen. 27 von 36 Pat. zeigten (75%; 14 SI-NET; 4 CUP-NET; 9 P-NET) im iStaging ein PD, 3 (8%) ein PR (mit chirurg. Therapieanschluss), 5 (14%) Toxizität (Nephrotox., 3; Hämatotox., 1; Tumorlyse-Syndr., 1) und 1 Pat. (3%) ist verstorben. Im Falle eines PD wurde die PRRT abgebrochen und die Pat. einem frühzeitigen Therapiewechsel unterzogen [mTOR, 10 (37%); Chemo, 9 (33%); TKI, 3 (11%); lokalablative Verfahren, 3 (11%); BSC, 2 (7%)]. Pat. mit 4 Zyklen PRRT zeigten ein medianes PFS von 38,0 Monaten (95%-Konfidenzintervall, 30,3-45,7 Monate). [1] [2] Schlussfolgerungen/Conclusions Das iStaging führte in 23% der Pat. zu einem Abbruch der PRRT aufgrund von PD. 3 Patienten konnten einer kurativ intendierten chirurgischen Therapie zugeführt werden. Durch die frühzeitige Selektion im iStaging zeigten Pat. mit 4 Zyklen PRRT ein verlängertes medianes PFS im Vergleich zur Literatur (38,0 vs. 28,4-30,0 Monate; 1,2). Diese Ergebnisse müssen durch weitere Studien validiert werden. Article published online: 30 March 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany